Product image of Kabazitaksel Teva (Cabazitaxel) supplied by GNH India

Kabazitaksel Teva

Active Ingredient:
Cabazitaxel
Origin:
EU

Kabazitaksel Teva (Cabazitaxel)

Cabazitaxel, the active ingredient in Kabazitaksel Teva, is a taxane presented as an injectable formulation for intravenous use. It is indicated for metastatic castration‑resistant prostate cancer in patients who have previously received docetaxel therapy.

GNH India supplies Kabazitaksel Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. Our network ensures timely delivery and regulatory compliance for hospitals, pharmacies and cancer treatment facilities.

Manufacturer / TM Owner

Teva B.V

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Cabazitaxel is a taxane chemotherapy used in the treatment of advanced prostate cancer.

  • Metastatic castration‑resistant prostate cancer (mCRPC) after docetaxel: extends overall survival in patients with disease progression.
  • Hormone‑refractory prostate cancer: provides a chemotherapy option when hormonal therapies have failed.
  • Advanced prostate carcinoma: used when the disease progresses despite prior taxane therapy.

How It Works

  • Cabazitaxel binds to the β‑tubulin subunit of microtubules, promoting polymerization and stabilizing the microtubule network. This prevents depolymerization, disrupts mitotic spindle formation, arrests cell division in the G2/M phase, and ultimately triggers apoptosis of rapidly dividing cancer cells.

Side Effects

Cabazitaxel is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Neutropenia: marked reduction in neutrophil count.
  • Fatigue: persistent tiredness affecting daily activities.
  • Alopecia: loss of hair on the scalp and body.
  • Nausea and vomiting: gastrointestinal upset.
  • Diarrhea: loose stools that may require supportive care.
  • Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects

  • Febrile neutropenia: fever with low neutrophil count requiring hospitalization.
  • Severe infections: opportunistic bacterial or fungal infections.
  • Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis.
  • Hepatic toxicity: significant elevation of liver enzymes.
  • Pulmonary toxicity: interstitial lung disease or pneumonitis.
  • Mucositis: painful inflammation of the mucous membranes.

Precautions & Warnings

When using Cabazitaxel, clinicians should observe several safety measures to minimize risks.

  • Monitor blood counts: perform regular complete blood count tests to detect neutropenia.
  • Assess liver function: check hepatic enzymes before each cycle.
  • Evaluate for infection: postpone treatment if active infection is present.
  • Use caution in elderly patients: dose adjustments may be needed.
  • Avoid concurrent myelosuppressive agents: reduce risk of severe bone‑marrow suppression.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Cabazitaxel may interact with other medicines, affecting its safety or effectiveness.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase cabazitaxel exposure.
  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce cabazitaxel efficacy.
  • Other myelosuppressive agents: compound bone‑marrow toxicity.
  • Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (e.g., warfarin, DOACs): heightened bleeding risk.
  • CYP2C8 substrates (e.g., paclitaxel): possible altered metabolism.
  • QT‑prolonging drugs (e.g., quinidine): monitor cardiac rhythm.
  • Electrolyte‑altering medications (e.g., diuretics): watch for arrhythmias.

Frequently Asked Questions

Kabazitaksel Teva contains cabazitaxel, a taxane chemotherapy indicated for metastatic castration‑resistant prostate cancer in patients whose disease has progressed after prior docetaxel therapy. It is used to improve survival in this advanced disease setting.

Cabazitaxel binds to β‑tubulin, stabilizing microtubules and preventing their depolymerisation. This blocks mitotic spindle formation, arrests cell division in the G2/M phase, and triggers programmed cell death in rapidly proliferating cancer cells.

The dose of Kabazitaksel Teva is determined by the treating oncologist based on the patient’s clinical status, body surface area, and laboratory parameters. Specific dosing regimens are outlined in the prescribing information and should not be altered without medical guidance.

Safety data for cabazitaxel in pregnancy and lactation are limited. The drug is classified as contraindicated during pregnancy because of potential fetal harm, and breastfeeding is not recommended while receiving treatment.

To order Kabazitaksel Teva, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

The primary alternative taxane is docetaxel. Cabazitaxel retains activity in tumors that have become resistant to docetaxel, offering a treatment option after docetaxel failure. Both share similar toxicity profiles, but cabazitaxel may have a higher incidence of neutropenia while providing additional survival benefit in the resistant setting.

Kabazitaksel Teva should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The product is supplied as a lyophilised powder for reconstitution; handling should follow aseptic techniques in a qualified pharmacy or clinical setting.

Kabazitaksel is given as an intravenous infusion after reconstitution with the appropriate diluent. The infusion is administered by a qualified healthcare professional, typically over a period of 30 minutes to one hour, according to the prescribing information.

The most serious risks include febrile neutropenia, severe infections, hypersensitivity reactions, hepatic toxicity, and pulmonary complications such as interstitial lung disease. Patients should be monitored closely for signs of infection, liver enzyme elevation, and respiratory symptoms throughout treatment.

Kabazitaksel should be avoided in patients with known hypersensitivity to cabazitaxel or any excipients, those with uncontrolled active infections, and individuals receiving concurrent strong myelosuppressive therapy unless medically justified. Caution is also advised for patients with severe hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Cabazitaxel

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT